A Phase 3 interventional study of Bremelanotide and Placebo in Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies, Inc. Completed at 91 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Palatin Technologies, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 11th largest by enrollment of the 59 interventional ones that give a count, is the only one that started in 2014, is one of 26 in phase 3, and was the 41st registered.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
Browse Sexual Dysfunctions, Psychological studies →3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:
Urological Research Network, LLC · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
San Diego Sexual Medicine · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 27 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 723 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Median enrollment 196 across the 59 interventional studies, 18 across the 1 observational. Of the 53 that completed or were terminated, 20 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 62 have an industry lead sponsor. The 10 most frequent:
Palatin Technologies, Inc is the lead sponsor of 11 studies on the registry; none are open to participants now.
Palatin Technologies, Inc has 4 studies filed under Sexual Dysfunctions, Psychological — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Dysfunctions, Psychological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT06458049Dana-Farber Cancer InstituteSexual Health and Rehabilitation Online (SHAREonline) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
This will be a multicenter, randomized, placebo-controlled, parallel group study in up to 80 sites in the United States of America (USA) and Canada to evaluate the efficacy and safety of a fixed dose of SC BMT versus placebo on an as-needed basis under conditions of home use in premenopausal women with HSDD (with or without decreased arousal).
The study will consist of 2 phases: (1) Core Study: 4-week no-treatment qualification period, a 4-week single-blind placebo treatment period (baseline), and a 24-week double-blind treatment period where participants will self-administer placebo or BMT 1.75 mg SC via an autoinjector; and (2) Extension Phase: a 52-week open-label treatment period during which all subjects will receive BMT 1.75 mg.
Primary Objective
Secondary Objectives
Main Inclusion Criteria:
Main Exclusion Criteria:
(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks (OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks
Drug: Bremelanotide
(Main Study) PBO administered SC on an as-desired basis for 24 weeks (OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks
Drug: Bremelanotide · Other: Placebo
A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
Also known as: BMT, PT-141
Placebo
Also known as: PBO
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.
As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain. FSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)
As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (Female Sexual Distress Scale - Desire Arousal Orgasm) (item 13).: co-primary endpoint - FSDS-DAO bothered by low desire item 13. Responses range from 0 (never) to 4 (always). Decreasing scores on this scale represent an increase in sexual desire (positive outcome).
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration
Patient's change, from baseline to end of study (EOS), in the number of Satisfying Sexual Events (SSEs), as measured by a response of 'Yes' to question 10 (Q10) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). The end point was calculated as the number of events during the last 4 weeks of treatment with Q10 = Yes minus the number of baseline events with Q10 = Yes.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Desire Score (Q3) From FSEP-R
Scores range from 0 (no desire) to 3 (high desire) for an individual encounter. Change from baseline is computed as the mean of the scores from all encounters for a subject in the last 28 days minus the mean of the scores from all encounters for the subject in the last 28 days before Visit 3. Only FSEP-R data pertaining to encounters recorded within 72 hours of the encounter are included.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R
Patient's change, from baseline to end of study (EOS), in mean satisfaction with desire score, as measured by a response to question 4 (Q4) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). Responses range from 1 (Not at all satisfied) to 4 (Completely satisfied).
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the FSDS-DAO Total Score
FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm Scores range from 0 (never feel bothered) to 60 (always feel bothered).
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total FSFI Total Score
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R
FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R
FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO
FSDS-DAO = Female Sexual Distress Scale-Desire/Arousal/Orgasm. The outcome reported is the mean score from the 15-item self assessment. The result is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a better outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Total Number of SSEs
Change from Baseline to EOS in the total number of satisfying sexual events SSEs that occurred within 16 hours of a study drug dosing and reported within 72 hours. A higher value indicates a better outcome.
Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
Time frame: 24 weeks (Main Study)
Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase
FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome. The score is the mean change from Baseline observed at EOS (Baseline score - EOS score) for FSDS-DAO Item 13 (feeling bothered by low sexual desire).
Time frame: 24 weeks (Main Study)
Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase
Mean change from Baseline to EOS in the number of satisfying sexual events SSEs that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number reflects a positive outcome.
Time frame: 24 weeks (Main Study)
Core ("Main") Study consisted of a 4-week no drug Screening period, followed by a 4-week single blind PBO period, first dose administered in-clinic. Following the end of single-blind period, which served as Baseline, eligible subjects were then randomized to a 24-week double-blind outpatient treatment period, first dose administered in-clinic.
| Milestone | Placebo PBO/BMT | Bremelanotide BMT/BMT |
|---|---|---|
| Started | 326 | 327 |
| Received intervention | 319 | 324 |
| Completed | 274 | 190 |
| Not completed | 52 | 137 |
| Milestone | Placebo PBO/BMT | Bremelanotide BMT/BMT |
|---|---|---|
| Started | 239 | 124 |
| Completed | 95 | 49 |
| Not completed | 144 | 75 |
As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain. FSFI = Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. Its six subscales assess desire, arousal, lubrication, orgasm, satisfaction, and pain, by summing individual items that comprise the subscale and multiplying the sum by a factor, resulting in a score ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.54 ± 1.106 | 0.24 ± 0.994 |
| Open label extension | 1.30 ± 1.105 | 0.77 ± 1.138 |
As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (Female Sexual Distress Scale - Desire Arousal Orgasm) (item 13).: co-primary endpoint - FSDS-DAO bothered by low desire item 13. Responses range from 0 (never) to 4 (always). Decreasing scores on this scale represent an increase in sexual desire (positive outcome).
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | -0.73 ± 1.203 | -0.36 ± 1.082 |
| Open label extension | -1.7 ± 1.21 | -0.9 ± 1.10 |
Patient's change, from baseline to end of study (EOS), in the number of Satisfying Sexual Events (SSEs), as measured by a response of 'Yes' to question 10 (Q10) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). The end point was calculated as the number of events during the last 4 weeks of treatment with Q10 = Yes minus the number of baseline events with Q10 = Yes.
| events | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.0 ± 1.44 | -0.1 ± 1.35 |
| Open label extension | 0.28 ± 1.457 | 0.10 ± 1.189 |
Scores range from 0 (no desire) to 3 (high desire) for an individual encounter. Change from baseline is computed as the mean of the scores from all encounters for a subject in the last 28 days minus the mean of the scores from all encounters for the subject in the last 28 days before Visit 3. Only FSEP-R data pertaining to encounters recorded within 72 hours of the encounter are included.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.0 ± 1.09 | 0.1 ± 0.92 |
| Open label extension | 0.66 ± 0.975 | 0.38 ± 1.107 |
Patient's change, from baseline to end of study (EOS), in mean satisfaction with desire score, as measured by a response to question 4 (Q4) of the Female Sexual Encounter Profile-Revised questionnaire (FSEP-R). Responses range from 1 (Not at all satisfied) to 4 (Completely satisfied).
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.2 ± 1.15 | 0.0 ± 0.96 |
| Open label extension | 0.93 ± 1.141 | 0.59 ± 1.054 |
FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm Scores range from 0 (never feel bothered) to 60 (always feel bothered).
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | -9.2 ± 13.86 | -5.5 ± 12.27 |
| Open label extension | -21.4 ± 13.96 | -12.0 ± 13.66 |
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The FSFI total score is on a scale ranging from 2 to 36. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 2.69 ± 7.317 | 0.95 ± 5.963 |
| Open label extension | 7.71 ± 8.076 | 3.95 ± 6.740 |
FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.1 ± 1.11 | -0.1 ± 0.93 |
| Open label extension | 0.65 ± 1.035 | 0.43 ± 1.029 |
FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (not at all aroused) to 3 (highly aroused) for an individual encounter. A higher score indicates a better outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.2 ± 1.20 | -0.1 ± 1.02 |
| Open label extension | 0.99 ± 1.170 | 0.60 ± 1.116 |
FSDS-DAO = Female Sexual Distress Scale-Desire/Arousal/Orgasm. The outcome reported is the mean score from the 15-item self assessment. The result is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | -0.6 ± 1.24 | -0.4 ± 1.07 |
| Open label extension | -1.5 ± 1.23 | -1.0 ± 1.12 |
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a better outcome.
| score on a scale | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | 0.66 ± 1.596 | 0.16 ± 1.240 |
| Open label extension | 1.46 ± 1.724 | 1.08 ± 1.581 |
Change from Baseline to EOS in the total number of satisfying sexual events SSEs that occurred within 16 hours of a study drug dosing and reported within 72 hours. A higher value indicates a better outcome.
| events | Bremelanotide BMT/BMT | Placebo PBO/BMT |
|---|---|---|
| Main study | -0.1 ± 1.76 | -0.2 ± 1.79 |
| Open label extension | 0.65 ± 1.676 | 0.05 ± 1.553 |
FSFI = Female Sexual Function Index: a multidimensional self-report instrument for the assessment of female sexual function. The score is on a scale ranging from 1.2 to 6. Increasing scores on this scale represent an increase in sexual desire and is a positive outcome.
| score on a scale | Bremelanotide BMT | Placebo PBO |
|---|---|---|
| Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase | 0.69 ± 1.114 | 0.23 ± 0.933 |
FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 ("never") to 4 ("always"). A higher score indicates a worse outcome. The score is the mean change from Baseline observed at EOS (Baseline score - EOS score) for FSDS-DAO Item 13 (feeling bothered by low sexual desire).
| score on a scale | Bremelanotide BMT | Placebo PBO |
|---|---|---|
| Change From Baseline to End of Study in the Total Score for FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase | -0.9 ± 1.23 | -0.3 ± 1.05 |
Mean change from Baseline to EOS in the number of satisfying sexual events SSEs that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number reflects a positive outcome.
| events | Bremelanotide BMT | Placebo PBO |
|---|---|---|
| Efficacy of a Fixed Dose of Bremelanotide, as Measured by a Change From Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase | 0.1 ± 1.66 | -0.1 ± 1.37 |
Collected over 6 months (Main study), 12 months (Open Label study). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bremelanotide (Main Study) | 0/324 (0%) | 4/324 (1.2%) | 255/324 (78.7%) |
| Placebo (Main Study) | 0/319 (0%) | 1/319 (0.3%) | 160/319 (50.2%) |
| Bremelanotide (OLE) | 0/124 (0%) | 0/124 (0%) | 95/124 (76.6%) |
| Placebo (OLE) | 0/239 (0%) | 2/239 (0.8%) | 200/239 (83.7%) |
| Event | Bremelanotide (Main Study) | Placebo (Main Study) | Bremelanotide (OLE) | Placebo (OLE) |
|---|---|---|---|---|
| Cerebrovascular accidentCardiac disorders | 0/324 | 0/319 | 0/124 | 1/239 |
| EndometriosisPregnancy, puerperium and perinatal conditions | 0/324 | 0/319 | 0/124 | 1/239 |
| ColitisGastrointestinal disorders | 0/324 | 1/319 | 0/124 | 0/239 |
| Abdominal hernia obstructiveGastrointestinal disorders | 1/324 | 0/319 | 0/124 | 0/239 |
| Peritoneal hemorrhageGastrointestinal disorders | 1/324 | 0/319 | 0/124 | 0/239 |
| VomitingGastrointestinal disorders | 1/324 | 0/319 | 0/124 | 0/239 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/324 | 0/319 | 0/124 | 0/239 |
| HeadacheNervous system disorders | 1/324 | 0/319 | 0/124 | 0/239 |
| Ovarian cyst rupturedReproductive system and breast disorders | 1/324 | 0/319 | 0/124 | 0/239 |
| Event | Bremelanotide (Main Study) | Placebo (Main Study) | Bremelanotide (OLE) | Placebo (OLE) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 138/324 | 7/319 | 46/124 | 109/239 |
| FlushingVascular disorders | 84/324 | 2/319 | 24/124 | 65/239 |
| SunburnInjury, poisoning and procedural complications | 10/324 | 33/319 | 12/124 | 33/239 |
| HeadacheNervous system disorders | 32/324 | 8/319 | 13/124 | 31/239 |
| Upper respiratory tract infectionInfections and infestations | 22/324 | 25/319 | 11/124 | 17/239 |
| Injection site painGeneral disorders | 15/324 | 20/319 | 3/124 | 20/239 |
| Urinary tract infectionInfections and infestations | 13/324 | 21/319 | 9/124 | 6/239 |
| FatigueGeneral disorders | 12/324 | 1/319 | 4/124 | 17/239 |
| VomitingGastrointestinal disorders | 17/324 | 0/319 | 3/124 | 15/239 |
| Injection site reactionGeneral disorders | 18/324 | 3/319 | 2/124 | 14/239 |
A total of 653 subjects were randomized into the double-blind period of the study; 10 subjects were not dosed, therefore total = 643. A total of 363 of the 464 (78.2%) subjects who completed the Core Study Phase continued into the optional OLE Study Phase.
| Age, Continuous(Years) | Bremelanotide (BMT/BMT) | Placebo (PBO/BMT) | Total |
|---|---|---|---|
| Main | 38.4 ± 6.95 | 38.5 ± 7.22 | 38.5 ± 7.08 |
| OLE | 38.5 ± 6.72 | 38.8 ± 6.93 | 38.7 ± 6.85 |
| Sex: Female, Male(Participants) | Bremelanotide (BMT/BMT) | Placebo (PBO/BMT) | Total |
|---|---|---|---|
| Main — Female | 324 | 319 | 643 |
| Main — Male | 0 | 0 | 0 |
| OLE — Female | 124 | 239 | 363 |
| OLE — Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Bremelanotide (BMT/BMT) | Placebo (PBO/BMT) | Total |
|---|---|---|---|
| Main — Hispanic or Latino | 33 | 31 | 64 |
| Main — Not Hispanic or Latino | 291 | 288 | 579 |
| Main — Unknown or Not Reported | 0 | 0 | 0 |
| OLE — Hispanic or Latino | 13 | 20 | 33 |
| OLE — Not Hispanic or Latino | 111 | 219 | 330 |
| OLE — Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bremelanotide (BMT/BMT) | Placebo (PBO/BMT) | Total |
|---|---|---|---|
| Main — American Indian or Alaska Native | 3 | 1 | 4 |
| Main — Asian | 2 | 3 | 5 |
| Main — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Main — Black or African American | 44 | 42 | 86 |
| Main — White | 273 | 269 | 542 |
| Main — More than one race | 1 | 3 | 4 |
| Main — Unknown or Not Reported | 1 | 1 | 2 |
| OLE — American Indian or Alaska Native | 2 | 0 | 2 |
| OLE — Asian | 2 | 2 | 4 |
| OLE — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| OLE — Black or African American | 17 | 29 | 46 |
| OLE — White | 101 | 204 | 305 |
| OLE — More than one race | 1 | 3 | 4 |
| OLE — Unknown or Not Reported | 1 | 1 | 2 |
The record gives a start of Dec 2014, a primary completion of Jul 2016 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2020, 4 years 5 months after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremelanotide
Sexual Dysfunctions, Psychological →
Palatin Technologies, Inc